Akin Advises Pharmakon Advisors in $450 million Commitment to BioCryst Pharmaceuticals
Contact:
(New York) – Akin advised Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry, in its $450 million financing commitment to BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
BioCryst has elected to draw $300 million of the $450 million available to the company on the closing date. The remaining $150 million of committed capital can be drawn at the company’s option until September 2024.
To learn more about the transaction, click here.
The Akin team advising Pharmakon Advisors was led by partner Geoffrey Secol and included partners Nate Brown and David Snyder, senior counsel Miriam Foley and Jo-Ellyn Klein, counsel Ekaterina Lyashenko and associates Mendy Fox, Caroline Kessler, Diandra Molina and Lexi Rummel.
Akin is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #
People Mentioned in This News
